Eric Lefkofsky's Tempus Partners With The University Of Chicago To Improve Breast Cancer Treatment Plans

Doctors at the University of Chicago will have better technology to fight breast cancer with the help of Tempus. Eric Lefkofsky founded Tempus after a very personal experience. His wife was diagnosed with breast cancer, and the limited but jumbled information left him feeling confused and frustrated. He and longtime business partner Brad Keywell developed Tempus, a technology company focused on delivering personalized cancer care through technology.
Improved Breast Cancer Treatment At The University Of Chicago
Several major health facilities have been rolling out the use of Tempus in their facilities, and the University of Chicago is happy to join the list. Tempus is also based in Chicago. As part of the race toward a cure for breast cancer, Tempus announced that it would analyze data from about 1,000 breast cancer patients who were seeking care through the University of Chicago.

Data will help researchers fine-tune care plans for the patients. Also, the data will be used in the future to help patients with similar genetic profiles who have the same type of cancer. For example, if three people with a similar genetic profile to someone who is seeking care had success with one uncommon treatment while another treatment was unsuccessful for two people with a similar profile despite an overall high success rate among breast cancer patients in general, physicians would have access to that information. When patients show changes or their cancer mutates, the system also looks for similar people who had similar changes and what helped them.

Tempus said that the new program will also help doctors and researchers at the University of Chicago predict how patients will respond to specific treatments, and it should improve outcomes for the patients. One of the professors of human genetics at the University of Chicago said that there is little information about the survivors of breast cancer and their treatment plans even though it is one of the most common types of cancer. She pointed out that a lack of such important information puts doctors in the difficult position of developing treatment plans without crucial data to help patients make informed decisions.

Generalized data from limited studies means that patients are guessing, and they may lose hope if the expected outcome of a popular treatment is not the same for them. The professors, doctors and researchers at the University of Chicago were happy to work with Tempus to build the world's biggest clinically annotated molecular data collection for cancer patients. Tempus has been in operation since 2015, which means that there is already enough existing information gathered to help improve possible outcomes for breast cancer patients at the University of Chicago. Other medical teaching facilities such as Northwestern University, Rush University Medical Center and the University of Michigan have recently partnered with Tempus to improve their cancer treatment care and to contribute to the future of more accurate and personalized cancer treatment plans.
About Eric Lefkofsky
Eric Lefkofsky is the co-founder and CEO at Tempus. He is a founding partner of Lightbank, a venture fund investing in disruptive technology businesses. He is also the co-founder and Chairman of Groupon (NASDAQ: GRPN), a global e-commerce marketplace, and co-founder of Uptake Technologies, a leading predictive analytics platform for the world’s largest industries; Mediaocean, a leading provider of integrated media procurement technology; Echo Global Logistics (NASDAQ: ECHO), a technology-enabled transportation and logistics outsourcing firm; and InnerWorkings (NASDAQ: INWK), a global provider of managed print and promotional solutions. He co-chairs the Lefkofsky Family Foundation with his wife Liz to advance high-impact initiatives that enhance lives in the communities served. Lefkofsky serves as a Trustee of Lurie Children’s Hospital of Chicago, The Art Institute of Chicago, The Museum of Science and Industry and World Business Chicago. He is also Chairman of the Board of Trustees of Chicago’s Steppenwolf Theatre Company. Lefkofsky is an adjunct professor at the University of Chicago and author of Accelerated Disruption: Understanding the True Speed of Innovation. He graduated from the University of Michigan and received his Juris Doctor at University of Michigan Law School. For more information, visit lefkofsky.com, connect on LinkedIn and follow him on Twitter (@lefkofsky) and Facebook (@eplefkofsky).


Share